Carbapenems are a powerful class of antibiotics, often used as a last-resort treatment to eradicate 13 multidrug-resistant infections. In recent years, however, the incidence of carbapenem-resistant 14
compared to an untreated control. Significant expression changes were found in genes related to 23 motility, maltodextrin metabolism, the formate hydrogenlyase complex, and the general stress 24 response. To validate these transcriptomic findings, we used our lab's Facile Accelerated Specific 25 Therapeutic (FAST) platform to create antisense peptide nucleic acids (PNA), gene-specific 26 molecules designed to inhibit protein translation. FAST PNA were designed to inhibit the 27 pathways identified in our transcriptomic analysis, and each PNA was then tested in combination 28 with each carbapenem to assess its effect on the antibiotics' minimum inhibitory concentrations. 29
We observed significant treatment interaction with five different PNAs across six PNA-antibiotic 30 combinations. Inhibition of the genes hycA, dsrB, and bolA were found to re-sensitize CRE E. coli 31 to carbapenems, whereas inhibition of the genes flhC and ygaC was found to confer added 32 resistance. Our results identify new resistance factors that are regulated at the level of gene 33 expression, and demonstrate for the first time that transcriptomic analysis is a potent tool for 34 designing antibiotic PNA. 35
Introduction 38
In recent years, the emergence of carbapenem-resistant Enterobacteriaceae (CRE) has 39 been marked by the World Health Organization (WHO) as a critical priority for antibiotic 40 development. 1 Resistance to carbapenems, a subclass of the cell wall-targeting β-lactams that 41 are often termed antibiotics of last resort, 2 has become increasingly common in recent decades, 3-42 5 resulting in rising threats of infection mortality. [6] [7] [8] [9] In 2017, the Centers for Disease Control 43 estimated that, in the U.S., 13,100 infections and 1,100 deaths per year were caused by 44 carbapenem-resistant Enterobacteriaceae alone. 10 Furthermore, the WHO has called for further 45 investment in both basic research and clinical development for CRE pathogens, as the current 46 pipeline is not sufficient to address the threat. 11 Our study seeks to use transcriptomics both to 47 better understand carbapenem resistance and to design new methods to combat its development. 48
Each of these aims is facilitated by the application of our Facile Accelerated Specific Therapeutic 49 (FAST) platform, a semi-automated pipeline for the design, synthesis, and testing of antisense 50 peptide nucleic acids (PNA)-synthetic DNA analogues with peptide backbones that can inhibit 51 translation on a gene-specific basis. Here, FAST PNA allow us to validate our conclusions from 52 our transcriptomic analysis, and to restore carbapenem susceptibility to a CRE clinical isolate. 53
Structural modifications, particularly a trans-α-1-hydroxylethyl substituent at position 6, are 54 believed to endow carbapenems with higher stability against β-lactamases, 12-14 as well as broader 55 observed efficacy, 15,16 compared with other β-lactam drugs. However, increasing prevalence of 56 carbapenemase enzymes in Enterobacteriaceae-such as oxacillinase-48, metallo-β-57 lactamases, and Klebsiella pneumoniae carbapenemases-provide mechanisms for the 58 development of resistance. 3, 5, 17, 18 Multiple studies have found that pathogenic bacteria without 59 carbapenemases can acquire carbapenem resistance through the combination of β-lactamases 60 and outer membrane porin deficiencies (neither factor alone was sufficient for resistance), 19-23 61 resistance phenotype, and to determine whether PNA designed using transcriptomics could re-87 sensitize E. coli CUS2B to sub-MIC carbapenem concentrations. 88
Results 89 E. coli CUS2B: a multidrug-resistant Enterobacteriaceae with partial carbapenem resistance 90
To validate the E. coli CUS2B resistance phenotype observed in the clinic, we measured 91 the isolate's minimum inhibitory concentrations (MIC) for a variety of antibiotics from different 92 classes ( Fig. 1A) . We found that E. coli CUS2B was resistant to almost all antibiotics (based on 93 breakpoints defined by the Clinical & Laboratory Standards Institute 37 ), including multiple 94 penicillins and ertapenem. Two potent carbapenem antibiotics, meropenem and doripenem, were 95 the only drugs to which the clinical isolate was susceptible. To investigate this partial carbapenem 96 resistance, we focused on the E. coli CUS2B response to ertapenem and meropenem ( Fig. 1B) . 97
The structures of meropenem and ertapenem differ in the pyrrolidinyl ring's position 2 side chain 98 ( Fig. 1C ). Meropenem's substituent amide group is thought to be responsible for increased 99 potency against gram-negative organisms in comparison to imipenem. 38 At this position 100 ertapenem has a benzoate substituent group, which imbues the molecule with a net negative 101 charge and increases its lipophilicity, resulting in increased plasma half-life but decreased affinity 102 for membrane porins. 13 103
Resistance factor identification via whole-genome sequencing 104
We performed whole genome shotgun sequencing for two purposes: (1) to create a 105 genome assembly that could be used for antisense PNA design, and (2) to search for genomic 106 contributions to the resistance phenotype. Using the ARG-ANNOT database, 39 we found that the 107 strain encodes fifteen genes related to antibiotic resistance ( Fig 1D) , including six associated with 108 β-lactams either as penicillin binding proteins (PBPs) or β-lactamase enzymes. Four of these 109 six-labeled by ARG-ANNOT as ampC1, ampC2, ampH, and a generic PBP-are encoded 110 chromosomally, and have high-similarity homologues in E. coli reference strains (Table S1 ). The 111 generic PBP, which was found to identically match the protein sequence for E. coli MG1655 112 mrdA/PBP2, is known to bind both carbapenems tested; PBP2 is the PBP to which meropenem 113 and ertapenem demonstrate greatest activity. 18, 40, 41 The genes ampC1 and ampH show >96% 114 homology with E. coli MG1655 PBPs yfeW/PBP4B and ampH/AmpH, respectively, and neither 115 has been found to bind with carbapenems. The gene ampC2 shows 98% nucleotide homology 116 with E. coli MG1655 β-lactamase ampC/AmpC, but has ten altered codons from the reference 117 sequence (Table S1 ). Additionally, the -35 to -10 promoter region for the CUS2B ampC has four 118 mismatched nucleotides from the same promoter region in MG1655, which may alter its 119 expression level relative to the basal non-resistant levels in the reference strain. The remaining 120 two β-lactam-associated genes are plasmid encoded; these are the β-lactamases TEM-135 and 121 CMY-44. E. coli CUS2B also encodes the outer membrane porins OmpA, OmpC, and OmpF, the 122 mutation or downregulation of which may influence carbapenem efficacy. 19, 33, 42 These three 123 proteins have, respectively, 95%, 90%, and 90% nucleotide homology with the corresponding 124 genes in E. coli MG1655. 125
Profiling gene expression in response to ertapenem and meropenem treatment 126
In previous work, we have established the ability of PNA and the FAST platform to design 127 effective antibiotic potentiators through the use of genomic data, using either knockouts of 128 essential genes or resistance genes. 36, 43 Here, FAST PNA allow us to explore transcriptomic 129 analysis and determine whether it can be similarly useful in reversing a bacterial resistance 130 phenotype. First, to reveal possible non-genetic contributions to the strain's carbapenem 131 resistance profile, we exposed exponentially growing E. coli CUS2B to ertapenem and 132 meropenem and examined gene expression profiles after thirty and sixty minutes of treatment 133 ( Fig. 2A ). This exposure time was selected based on observations from others that 30-60 minutes 134 is favorable for locating gene expression changes specific to antibiotic exposure. [44] [45] [46] The short 135 time frame also greatly reduces the likelihood that the gene expression signal will be confounded 136 by the emergence of one or more mutant genotypes. E. coli CUS2B was diluted 1:20 from 137 overnight cultures and grown for 1 hour to exponential phase prior to treatment with 2 µg/mL of 138 ertapenem or 1 µg/mL of meropenem. Each carbapenem concentration is half of that required to 139 eradicate E. coli CUS2B under these culture conditions (conditions differ from Fig. 1 MIC assay) 140
We identified differentially expressed (DE) genes by comparing the RNA sequencing data 142 from ertapenem-and meropenem-treated samples to an untreated control at the same timepoint. 143
The DESeq R package 47 was used to evaluate significance and correct P-values for multiple 144 hypothesis testing. General expression trends were evaluated using hierarchical clustering across 145 genes and conditions ( Fig. 2B ). Conditions were found to cluster by timepoint rather than 146 antibiotic-an effect previously observed in a transcriptomic study of vancomycin-challenged 147
Staphylococcus aureus 48 -which suggests a generalized and transient antibiotic response. In our 148 analysis, we detected 41 transcripts that were DE in both treatments after 30 minutes of exposure, 149 six transcripts DE in both antibiotics after 60 minutes of exposure, and six that were DE in both 150 treatments at 30 and 60 minutes ( Fig. 2C , File S1). 151
The six DE genes common to all conditions are indicated in Fig. 2D . Two of these genes, 152 flhC and flhD, code for components of the transcriptional regulator FlhDC, which is responsible 153 for regulating motility-associated functions such as swarming and flagellum biosynthesis. 49 Both 154 flhC and flhD genes were significantly underexpressed at 30 and 60 minutes. Perhaps relatedly, 155 motility-associated gene ontology terms (GO:0040011: locomotion; GO:0071918: bacterial-type 156 flagellum dependent swarming motility) were significantly overrepresented 50 within the 30-minute 157 overlapping set, accounting for 26 of the total 41 genes ( Table S2 ). All 26 were underexpressed. 158 The gene ivy, an inhibitor of bactericidal vertebrate lysozymes, 52,53 was overexpressed in 161 both treatments at 30 and 60 minutes. Both lysozymes and carbapenems disrupt peptidoglycan 162 polymerization, although ivy is not known to interact with these antibiotics. Three other transcripts 163 of unknown function were overexpressed in all conditions: BTW13_RS03610 (ymgD superfamily), 164 BTW13_RS11940 (DUF1176 superfamily), and a transcript antisense to BTW13_RS17895 165 (putative lipoprotein, DUF1615 superfamily). 166
In the ertapenem response we find many more DE genes than in the meropenem 167 response, including 38 DE genes shared between the two time points (compared with none 168 shared across both meropenem time points). Within this set, we observed significant 169 overrepresentation of genes related to maltodextrin transport (mal operon, GO:0042956) and the 170 ferredoxin hydrogenase complex (hyc operon, GO:0009375). 50 All of these overrepresented 171 genes were found to be overexpressed in ertapenem treatments. Only three genes were 172 underexpressed in ertapenem at both 30 and 60 minutes: lptG, a member of the 173 lipopolysaccharide transport system, phoH, an ATP-binding protein, and cstA, a starvation-174 induced peptide transporter. Of the genes specific to the meropenem response, only the flagellar 175 biosynthesis proteins fliQ and fliT are related, and the downregulation of these genes did not 176 continue to the 60-minute timepoint. 177
We also searched for differential expression in outer membrane porin operon (omp) 178 genes, previously linked to carbapenem-resistance, 19,33,42 and resistance-related genes identified 179 by ARG-ANNOT. Of the omp operon, only ompF was found to be significantly DE in any condition 180 with respect to no treatment (underexpressed in meropenem, 30 minutes) ( were DE in any condition ( Fig. S3 , File S1). 185
Based on these observations, we chose three genes to target using PNA: hycA, malT, 186 and flhC. The former two genes were chosen to probe the hyc and mal operons for their 187 importance to resistance and their utility as antibiotic re-sensitization targets. The gene flhC was 188 chosen to validate the consistent downregulation of the FlhDC system and evaluate whether 189 further knockout of the gene would confer greater carbapenem resistance. 190
Differential expression of small RNA 191
In addition to total RNA sequencing, we performed small RNA sequencing to search for 192 resistance contributions and potential FAST PNA targets among short nucleic acids potentially 193 involved in gene regulation. Small RNA have been previously shown to influence bacterial stress 194 and antibiotic response. [54] [55] [56] We used an RNA isolation protocol that enriched for sRNA (see 195
Methods) prior to sequencing, and sequencing data were aligned to the E. coli UMN026 genome 196 (the reference that maximized alignment homology) using the Rockhopper 57 pipeline, which 197 allowed for identification of previously documented sRNA and novel RNAs. 198 We observe more overlap of DE genes between single time points than between 199 respective antibiotic treatments, suggesting a generalized and transient response similar to that 200 of total RNA expression ( Fig. 3A ). We find 22 sRNAs to be DE in at least two out of the four 201 conditions ( Fig. 3B ), including known regulatory sRNAs (dicF, ssrA), annotated short protein-202 coding genes (ilvB, acpP, bolA, csrA, ihfA, lspA), small putative protein-coding genes (dsrB, 203 yahM, ybcJ, ygdI, ygdR, ytfK), small transcripts antisense to coding genes (ygaC, hemN, 204 ECUMN_1534/5), and novel predicted transcripts. 205
From these lists we chose three genes to investigate with FAST PNA: bolA, dsrB, and 206 ygaC. bolA was chosen based on its relation to PBPs, AmpC, 58 and the cellular stress response, 59 207
whereas the latter two were chosen to discriminate between the two carbapenem responses. The 208 time course of gene expression for three small transcripts of interest is presented in Fig. 3C . We 209 found bolA to be overexpressed in meropenem and ertapenem at 60 minutes, which may indicate 210 that both antibiotics are being detected and able to activate bolA, but the subsequent response is 211 only effective against ertapenem. dsrB was overexpressed in ertapenem at both time points, but 212 in meropenem only at 30 minutes. Although the function of dsrB is unknown, it is controlled by σ S , 213 the general stress response and stationary-phase sigma factor. 60 The transcript antisense to ygaC 214 was overexpressed in meropenem at both timepoints but was not detected in ertapenem-treated 215 populations. The function of ygaC is unknown, but it is controlled by the Fur transcriptional dual 216 regulator, which suggests that it may have a role in stress response. 217
PNA antisense inhibition of RNA sequencing targets 218
The FAST platform comprises Design, Build, and Test modules for the creation of 219 antisense PNA (Fig. 4A ). In this study, we began our design process using transcriptomic data to 220 generate a list of target genes, which, together with a whole-genome assembly and genome 221 annotation, were used as inputs for the FAST tool PNA Finder. This tool was used to design 222 multiple antisense PNA candidates for each gene target, with 12-mer sequences-a length that 223 seeks to optimize both specificity 61-63 and transmembrane transport 64 -that were complementary 224 to mRNA nucleotide sequences surrounding the translation start codon. PNA Finder then filtered 225 this set of candidates to minimize the number of predicted off-targets within the E. coli CUS2B 226 genome, to maximize solubility, 65 and to avoid any self-complementing sequences. For the FAST 227
Build module, a single PNA for each gene target was selected and synthesized using Fmoc 228 chemistry, with the cell-penetrating peptide (KFF)3K attached at the N-terminus to improve 229 transport across the bacterial membrane. These PNA were then tested in E. coli CUS2B cultures 230 in combination with each carbapenem to determine whether the two treatments would interact as 231 predicted. A two-way ANOVA test was used to assess interaction significance, and normalized 232
S-values (see Methods) were used to compare the observed growth to the expected growth, as 233 predicted by the Bliss Independence Model for drug combinations. 66 234
Based on the results of our transcriptomic analysis, we selected three genes identified by 235 our total RNA sequencing analysis (hycA, malT, and flhC) and three genes identified by our small 236 RNA sequencing analysis (bolA, dsrB, and ygaC) to be targeted by FAST PNA. Differential 237 expression of flhC and bolA was observed in both carbapenems, while differential expression of 238 hycA, dsrB, and the operon controlled by malT was prevalent in the ertapenem response. The 239 transcript antisense to ygaC was overexpressed in both meropenem conditions, but the gene 240 itself was not differentially expressed. While we suspect that the ygaC antisense transcript 241 regulates the gene ygaC, PNA have not been established to interfere with ncRNA regulation. With 242 this in mind, we designed a PNA to bind to the ygaC sense transcript and inhibit protein 243 translation, to test the hypothesis that ygaC inhibition may confer greater meropenem resistance 244 in a similar manner to the flhC-targeted PNA. The genome assembly for the clinical isolate was 245 used by FAST to design multiple PNA for each selected gene, which were then screened for high 246 solubility, minimal self-complementarity, and zero off-target gene inhibition in E. coli CUS2B 247 (Table S3 ). Additionally, a scrambled-sequence nonsense PNA was designed to control for any 248 possible effects of the PNA or CPP independent of sequence. No effects were found with 249 nonsense PNA alone or in any nonsense PNA-antibiotic combination treatment ( Fig. S5 ). 250
We also designed a PNA to inhibit the translation of the chromosomal β-lactamase AmpC, 251 based on prior research showing that the enzyme can elevate ertapenem MICs. 67,68 This PNA 252 was also synthesized to assess the relative effectiveness of PNA targets selected using 253 transcriptomic analysis, in comparison to those selected on a genomic basis. We have previously 254
shown the ability to re-sensitize MDR bacteria by targeting β-lactamases. 43 In a combination of α-255 ampC (10 µM) in combination with ertapenem (1 µg/mL), we also observe significant synergistic 256 interaction, evidenced both by the growth curve endpoint and cell viability assay (Table 1, ampC grew similarly to cultures treated with meropenem alone, as expected. Although the 259 comparison of treatments in the cell viability assay did demonstrate significant interaction, the 260 data does not seem to indicate a combinatorial effect, as the fluorescence level is virtually 261 unchanged across the three treated conditions. Additionally, increasing the concentration of α-262 ampC to 15 µM could not resolve any effect, as the PNA alone was virtually lethal at this 263 concentration ( Fig. S6B) . 264
To determine whether transcriptomic analysis could be used by FAST to produce similar 265 re-sensitization effects, E. coli CUS2B was treated with each of the six PNA at a concentration of 266 10 µM in combination with sub-MIC carbapenem treatments (1 µg/mL ertapenem, 0.1 µg/mL 267 meropenem). We analyzed the cultures' endpoint optical densities and cell viabilities (via 268 resazurin assay) to assess interaction between the two treatments, based on a comparison with 269 each individual PNA and carbapenem treatment. At these concentrations of PNA and antibiotic, 270
we observed significant synergy between the PNAs α-hycA, α-dsrB, and α-bolA and ertapenem, 271
with S-values of 0.23, 0.85 and 0.83 for their respective endpoint optical densities (Table 1, The PNA α-ygaC, α-malT, and α-flhC at concentrations of 10 µM did not exhibit significant 277
interaction with ertapenem at 1 µg/mL or meropenem at 0.1 µg/mL ( Fig. S7, Fig. S8A ). 278
As noted above, we hypothesized that a combination of the PNA α-flhC or α-ygaC with 279 carbapenem treatment would result in a recovery of growth and increased resistance. However, 280
in the PNA-carbapenem combination treatments we did not observe growth recovery relative to 281 the carbapenem-only treatment for the sub-MIC concentrations. We hypothesized that effects at 282 such concentrations could be difficult to resolve, given that the growth curves of carbapenem-283 treated E. coli CUS2B reached endpoints similar to the untreated condition ( Fig. S7A, Fig. S8A ). 284
To examine this hypothesis, we treated the clinical isolate with α-flhC or α-ygaC at 10 µM in 285 combination with ertapenem or meropenem at their MICs (Fig. 1C ; 2 µg/mL and 0.25 µg/mL, 286 respectively). At these higher carbapenem concentrations, we observed significant antagonistic 287 interaction between both PNA and meropenem in combination (S = -0.9 and S = -0.93, 288 respectively, for endpoint optical density) (Table 1, Fig. 4E ), whereas a combination of either PNA 289 with ertapenem showed no growth rescue (Table 1, Fig. S8B ). 290 In this study, we sought to combine transcriptomic analysis of carbapenem resistance with 297 our FAST platform, both to better understand the partial carbapenem resistance profile of E. coli 298 CUS2B, and to engineer carbapenem re-sensitization in the clinical isolate. Our results offer 299 insights into pathways that are important for the development of resistance, identifying multiple, 300 and demonstrate the first use of transcriptomics in the design of PNA for antibiotic applications. 301
To begin our analysis of the clinical isolate, we first used whole genome sequencing to 302 search for any possible genomic resistance factors. We identified 15 genes related to antibiotic 303 resistance, including six related to β-lactam antibiotics. None of these genes are dedicated 304 carbapenemases, although the chromosomal E. coli AmpC β-lactamase is present. The basal 305 expression of AmpC in wild-type E. coli is not enough to confer resistance to beta-lactams, but 306 mutation-induced overproduction of the chromosomal AmpC in Enterobacteriaceae has been 307 shown to promote antibiotic resistance. 33,42,69-71 Furthermore, when coupled with porin 308 deficiencies, AmpC expression can increase enterobacterial resistance to ertapenem while 309 retaining susceptibility to other carbapenems. 23,67,68,72,73 Our genomic analysis identified ten codon 310 mutations in the E. coli CUS2B AmpC compared with E. coli MG1655, as well as four nucleotide 311 mutations in the -35 to -10 promoter region. Furthermore, we identified numerous mutations of 312 the E. coli CUS2B omp operon porin genes. It is possible that these mutations contribute to the 313 ertapenem-resistant/meropenem-sensitive resistance profile that we observe in this clinical 314 isolate. Using the FAST platform, we were able to design an anti-AmpC PNA to knockdown the 315 translation of the β-lactamase and determine whether it has a significant role in resistance. As 316 expected, we observed a strong significant synergistic combination between α-ampC and 317 ertapenem, but not between α-ampC and meropenem. These observations agree with prior work 318 from our lab that establish β-lactamases as viable re-sensitization targets, and serve as a basis 319 of comparison for our transcriptomics-based PNA. 320
Transcriptomic analysis of carbapenem-challenged E. coli CUS2B revealed a much 321 greater gene expression change in response to ertapenem than to meropenem: 485 DE genes 322 were unique to ertapenem treatment versus 19 DE genes unique to meropenem. This may 323 suggest the recognition of ertapenem and resultant response activation, in addition to innate basal 324 resistance factors. In the DE analysis, we find no significant difference between the expression of 325 outer membrane porin genes ompA, ompC, and ompF in the ertapenem experiments when 326 compared to the meropenem experiments or the untreated conditions. Though ompF was found 327 to be slightly underexpressed in meropenem after 30 minutes with respect to untreated conditions, 328 the lack of differential expression in the ertapenem-treated conditions leads us to conclude that 329 transcriptomic control of this gene is not a major resistance factor for E. coli CUS2B. As discussed 330 above, the downregulation and deletion of these genes has previously been linked to 331 carbapenem-resistance, 19,33,42,67 but, if this mechanism is active in E. coli CUS2B, it does not 332 appear to be regulated by transient gene expression. Similarly, none of the resistance-related 333 genes identified in our genomic analysis were found to be DE in any carbapenem treatment 334 condition, and we may conclude that transcriptomic control of these genes does not contribute to 335 the E. coli CUS2B resistance phenotype. Notably, though, this does not rule out a constitutively 336 higher expression of the AmpC β-lactamase nor constitutively lower expression of porin genes, 337 relative to the reference strain, 338
To determine the transient gene expression changes that contribute to the carbapenem 339 resistance phenotype, we analyzed differential expression overlaps between the each of the four 340 samples (two carbapenems, two time points each). The most apparent trend was an 341 overwhelming underexpression of motility-related genes after 30 minutes of exposure to both 342 antibiotics, an effect that lessened after 60 minutes of exposure. This response is consistent with 343 prior work that has noted a decreased expression of motility genes in response to generalized 344 environmental stressors. 74-77 Two of these motility-related genes, flhC and flhD, were consistently 345 DE in both treatments at both timepoints, along with the lysozyme inhibitor ivy, an RNA antisense 346 to a putative lipoprotein, and two transcripts of unknown function. 347
We used antisense PNA to probe the resistance contributions of the flhDC operon. 348
Interestingly, we observed significant antagonistic interaction between PNA inhibition of FlhC 349 translation and meropenem treatment, but not ertapenem treatment. The deletion of the FlhDC 350 regulator has been shown in E. coli to eliminate motility, and has been shown to cause 351 downregulation of a large number of genes that are primarily related to chemotaxis/motility and 352 flagellar surface structures. 74 It is striking that this resistance factor can be artificially induced to 353 so effectively rescue the E. coli CUS2B strain from carbapenem challenge, and that the effect is 354 stronger than any response that the cell naturally activates, even over the course of 24 hours. We next examined the ertapenem-specific response in an effort to use transcriptomics to 360 engineer carbapenem re-sensitization. We identified a total of 38 transcripts that were uniquely 361 DE in ertapenem-treated samples. In this set we identified two operons-the mal operon 362 (maltodextrin metabolism) and the hyc (formate hydrogenlyase complex) operon-that are 363 consistently overexpressed. We designed and synthesized PNA inhibitors for malT, which, while 364 not DE, is an activator of the overexpressed mal operon, as well as the DE gene hycA, in order 365 to evaluate and interfere with the clinical isolate's response to ertapenem. We observed significant 366 synergistic growth inhibition between α-hycA and ertapenem, but not meropenem, while 367 combinations of α-malT with the carbapenems did not produce significant treatment interaction. 368
The genes of the hyc operon code for formate hydrogenlyase complex, which mediates 369 formate oxidation and has shown a potential connection to ATP synthesis. 78 However, previous 370 mutational analysis of hycA has provided evidence that the protein HycA works as a negative 371 regulator of this system, as increased formate dehydrogenase activity was observed following its 372 deletion. 79,80 Based on our observations, the upregulation of the formate hydrogenlyase complex 373 is likely important to the E. coli CUS2B's ertapenem resistance, but requires commensurate 374 upregulation of the HycA regulator. The absence of this regulator results in the observed 375 synergistically toxic effect when α-hycA is combined with ertapenem, an effect not observed in 376 the meropenem response because the system is not activated by the antibiotic. These results 377 validate the role of formate metabolism in the carbapenem response, and support the conclusion 378 that transcriptomic data is valuable for engineering antibiotic re-sensitization in resistant 379
enterobacteria. 380
In addition to applying FAST PNA to gene targets identified by total RNA sequencing, we 381 also analyzed differential expression of small RNA in search of potential resistance factors. We 382 identified 22 transcripts that were differentially expressed across one or more of the treatment 383 conditions and timepoints, and selected three genes to be targeted by FAST: dsrB, bolA, and 384 ygaC. dsrB and bolA are translated into short proteins, but no annotation for the ygaC antisense 385 complement has been identified, leading to the hypothesis that the transcript serves as a 386 regulatory RNA for the gene. 387
Perhaps the most dramatic result of this study was the effectiveness of α-dsrB and α-bolA 388 in restoring carbapenem susceptibility to E. coli CUS2B. At 10 µM, each PNA showed significant 389 synergistic interaction with sub-MIC ertapenem, and α-bolA showed significant synergistic 390 interaction with sub-MIC meropenem at a concentration of 15 µM. Surprisingly, each S-value for 391 these three combinations (0.85, 0.83, and 0.61) was comparable to the value of α-ampC (S = 392 0.76). Each of these results is consistent with the predictions of the RNA sequencing: dsrB was 393 found to be overexpressed at both time points for ertapenem, but only at 30 minutes for 394 meropenem, and bolA was found to be overexpressed in both at 60 minutes. Although little is 395 known about dsrB, it is reported to be regulated by the general stress response sigma factor 396
RpoS. 60 Inhibition of DsrB translation abolished bacterial growth in combination with ertapenem 397 (S = 0.85, Fig. 4) , which is consistent with previous research that has associated β-lactam 398 antibiotics with induction of the RpoS general stress response regulon. Importantly, though, our 399 results confirm that activation of DsrB is specific to the transcriptome of a resistance phenotype, 400
and that its upregulation is a necessary component of the CRE response in this clinical isolate. 401
BolA is known to be induced under a variety of stress conditions 59 and is involved in biofilm 402 induction 81-83 and protective morphological changes 58 for E. coli cells. Perhaps most important, 403 though, is that BolA has been shown to control expression of the proteins PBP5 and PBP6 in E. 404 coli, as well as the β-lactamase AmpC. 58 Although neither E. coli PBP5 nor PBP6 has been shown 405 to bind meropenem or ertapenem-these antibiotics are known to bind preferentially to PBP2 and 406 PBP3 18,24,41,72 -our previous results indicate that AmpC contributes to the observed ertapenem-407 resistance phenotype. The effect of α-bolA differs from that of α-ampC, however, in its effect on 408 meropenem efficacy. This finding provides strong evidence that BolA is important to the general 409 carbapenem response in E. coli, and is not merely incidentally upregulated in the meropenem 410 response, as might be concluded from transcriptomic analysis alone. Additionally, the success 411 of both the α-dsrB and α-bolA in PNA-carbapenem combination treatments-in three experiments 412 fully abolishing growth (Fig. 4) -represents the first time that transcriptomic analysis has been 413 used to design PNA antibiotics, and, importantly, shows equal if not better efficacy than the 414 genome-derived PNA α-ampC. Further development of this strategy will aid in the design of 415 antisense inhibitors to target pathogenic species about which less information-essential genes, 416 genome annotation, etc.-is readily available. 417
The final PNA for which we find interaction with carbapenem treatment is α-ygaC. Similar 418 to α-flhC, this PNA showed the ability to rescue growth in E. coli CUS2B in cultures treated with 419 previously lethal meropenem concentrations, but did not replicate this effect in ertapenem-treated 420 cultures. Though we observed overexpression of the unannotated RNA transcript antisense to 421 ygaC, not the gene itself, the PNA demonstrated surprising effectiveness at inducing resistance. 422
These results affirm that the ygaC antisense transcript is likely controlling the gene's expression, 423
and suggest that ygaC downregulation is associated with a more broadly resistant phenotype. 424
The growth rescue in meropenem-treated conditions by both α-ygaC and α-flhC points to routes 425 that resistant bacteria may take towards developing broad resistance. Furthermore, the success 426 of α-ygaC, considering that it is a largely unstudied gene never before linked to antibiotic 427 resistance, demonstrates the specific utility of transcriptomics in the design of PNA for antibiotic 428
applications. 429
Resistance has been extensively studied at the genetic level, which has helped 430 researchers to understand many genetic factors that can contribute to resistance. However, 431 carbapenem resistance is not often studied at a transcriptomic level, and, when it is, the research 432 almost exclusively examines basal expression levels. [30] [31] [32] [33] [34] [35] In this work, we profiled the short-term 433 transient transcriptomic responses of a partially carbapenem-resistant clinical isolate of E. coli 434 and used our FAST platform to design PNA that uncovered the importance of multiple systems in 435 the development of this phenotype, including the regulators flhC, hycA, and bolA. Furthermore, 436 by inhibiting hycA, bolA, and dsrB with FAST PNA, we were able to re-sensitize the clinical isolate 437 to sub-MIC carbapenem concentrations. There are no small molecules known to inhibit the action 438 of any of these gene targets, which demonstrates the value of PNA inhibitors to fill in the gaps in 439 modern antibiotic discovery. This is the first time that transcriptomic analysis has been applied to 440 identify targets for antibiotic PNA applications, and it is striking how effective the transcriptome-441 derived PNA were in inducing carbapenem susceptibility to the CRE isolate. We find two such 442 PNA-carbapenem combinations that are more effective than the anti-β-lactamase PNA α-ampC. 443
In future research we will seek to develop these results into a means to consistently and 444 systematically re-sensitize MDR pathogens to carbapenems, and thus maintain the efficacy of 445 these antibiotics of last resort. 
Minimum inhibitory concentration assays 455
Three colonies were picked from a plate and used to inoculate three separate overnight 456 cultures in 1 mL CAMHB each. After 16 hours, the cultures were diluted 1:10,000 and treated with 457 a range of antibiotic concentrations, decreasing in 2-fold increments, in a 384 or 96-well 458 microplate using three biological replicates per condition. Growth in the plate was monitored with 459 a Tecan GENios (Tecan Group Ltd.) running Magellan™ software (v 7.2) at an absorbance of 460 590 nm every 20 minutes for 16 hours, with shaking between measurements. The minimum 461 inhibitory concentration was identified as the lowest antibiotic concentration preventing growth. 462
Genome sequencing 463
Five colonies were picked from a plate and resuspended in liquid culture. After 16 hours, 464 1 mL of culture was used for genomic DNA isolation with the Wizard DNA Purification Kit 465 (Promega). Approximately 2 µg of DNA was used to prepare a paired-end 250-bp sequencing 466 library with the Nextera XT DNA library kit. The library was sequenced on an Illumina MiSeq, 467 resulting in 407,910 reads (20X coverage). The de novo assembly is 5,325,941 bp in length with 468 a GC content of 50.59%. The largest contig is 394,969 bp, and the N50 is 100,215. The genome 469 contains 5,360 protein coding sequences, 114 RNA coding sequences, 82 tRNAs, 11 ncRNAs, 470 260 pseudogenes, and 2 CRISPR arrays. 471
The FASTQ files were filtered for quality using Trimmomatic (v0.32) 84 , in sliding window 472 mode with a window size of 4 bases, a minimum average window quality of 15 (phred 33 quality 473 score), and a read length of at least 36 bases. For resequencing, reads were aligned to various 474 E. coli RefSeq reference genomes using Bowtie 2 (v2.2.3) 85 . SAMTools (v0.1.19) 86 was used to 475 remove PCR duplicates and create indexed, sorted BAM files. Variants were called and filtered 476 using the Genome Analysis Toolkit (v2.4-9). 87 To pass the filter, a SNP had to meet the following CRISPRfinder 92 , and locating plasmids with PlasmidFinder 93 . 485
RNA-sequencing and differential expression analysis 486
Colonies were picked from a plate and resuspended in liquid culture. After 16 hours of 487 growth, the culture was diluted 1:20 into duplicate 15 mL cultures. These were grown for 1 hour, 488 then 3 mL from each was preserved in 2 volumes of RNAprotect. Each culture was divided into 489 three equal parts. No antibiotic was added to one part and antibiotic were added to the other two 490 for final concentrations of 2 μg/mL of ertapenem or 1 μg/mL of meropenem, corresponding to 491 50% of the MIC under these growth conditions (note that these conditions are different than the 492 procedures used to determine the MICs in Fig. 1) . After thirty and sixty minutes of growth, 1.5 mL 493 of culture was collected from each and stored in RNAprotect. Cultures were flash frozen in ethanol 494 and dry ice and stored at -80⁰C until the time of RNA extraction. 495
To extract RNA, samples were thawed and resuspended in 100 μL TE buffer with 0.4 496 mg/mL lysozyme and proteinase K. After incubation at room temperature for 5 minutes, 300 μL 497 of lysis buffer with 20 μL/mL β-mercaptoethanol was added to each and vortexed to mix. Each 498 lysis solution was split in half, with one half being processed for total RNA isolation and the other 499 for small RNA isolation. Total RNA was isolated using the GeneJet RNA Purification kit (Thermo 500 Scientific) followed by DNase treatment with the TURBO DNA-free kit (Ambion). Small RNA was 501 isolated using the mirVana miRNA isolation kit (Thermo Scientific). Concentration and A260/A280 502 were measured on a Nanodrop 2000 (Thermo Scientific). A minimum of 130 ng of RNA per 503 sample was submitted for sequencing library preparation. Quality was further assessed with a 504 Bioanalyzer (Agilent). Libraries were prepared using the RNAtag-Seq protocol, 94 wherein 505 individual samples are barcoded and pooled prior to ribosomal RNA treatment and cDNA 506 synthesis. Here, the total RNA samples were combined into one pool, and the small RNA enriched 507 samples were combined into a separate pool. The total RNA pool was fragmented via incubation 508
with FastAP buffer at 94°C. After another DNAse treatment, barcoded adapters were ligated with 509 T4 DNA ligase, then the samples were pooled and subjected to Ribo-Zero treatment. The prep 510 for small RNA libraries was similar, without the fragmentation or ribosomal RNA treatment steps. 511
Total RNA libraries were sequenced on a NextSeq 500 (Illumina) using a high output cycle 75-512 cycle run. Small RNA libraries were sequenced on a NextSeq with a medium output run, halted 513 after 75 cycles. 514 FASTQ files were demultiplexed with the barcode splitter function from the FastX 515 toolbox (http://hannonlab.cshl.edu/fastx_toolkit/, v0.0.13.2). The first seven base calls (containing 516 the barcode) were trimmed using FastX, then adapters were removed and all reads were trimmed 517 for quality using the sliding window mode in Trimmomatic (v0.32) 84 . Quality of the resulting FASTQ 518 files was validated with FastQC (http://www.bioinformatics.babraham.ac.uk/projects/fastqc/). For 519 total RNA data (including sense and antisense transcripts) and differential expression analysis, 520 reads were aligned to the draft assembly of the CUS2B genome (available as RefSeq 521 GCF_001910475.1) with Bowtie 2 (v2.2.3). An average of 16.5±3.2 million reads were 522 successfully mapped per sample. SAMTools (v0.1.19) was used to create bam files. HTSeq 523 (v0.6.1) 95 was used to build count tables for sense and antisense reads. DESeq 47 was used to 524 determine differentially expressed genes, with a pooled dispersion metric and a parametric fit. 525
Genes were considered significantly differentially expressed if the Benjamini-Hochberg adjusted 526 P-value was less than 0.05. For small RNA data, trimmed FASTQ files were submitted to 527
Rockhopper, 57 which mapped to the E. coli UMN026 genome (90,152±25,642 reads mapped per 528 sample) and performed differential expression analysis. Small RNA transcripts were considered 529 significantly DE if the Benjamini-Hochberg adjusted P-value was less than 0.05. 530
PNA design 531
PNA design was carried out using the PNA Finder toolbox. 36 The toolbox is built using 532 Python 2.7, the alignment program Bowtie 2, 85 the read alignment processing program 533 SAMtools, 86 and the feature analysis program BEDTools. 96 The toolbox takes a user-provided list 534 of gene IDs and cross-references the IDs against a genome annotation file to determine the 535 feature coordinates for each ID. The toolbox then uses these coordinates to extract PNA target 536 sequences of a user-specified length (12 bases in this study) and user-specified positions relative 537 to the start codon from a genome assembly FASTA file. PNA Finder provides a list of PNA 538 candidates (the reverse complements of the target sequences) and sequence warnings regarding 539 solubility and self-complementation. Finally, PNA Finder screens the list of PNA candidates 540 against a user-provided genome assembly (in this study, the genome for E. coli CUS2B) to search 541 for off-targets, and uses this analysis to filter the candidates into a final PNA list for synthesis. 542
PNA synthesis 543
PNA were synthesized using an Apex 396 peptide synthesizer (AAPPTec, LLC) with 544 solid-phase Fmoc chemistry at a 10 µmol scale on MBHA rink amide resin. Fmoc-PNA monomers 545 were obtained from PolyOrg Inc., with A, C, and G monomers protected with Bhoc groups. PNA 546 were synthesized with the N-terminal cell-penetrating peptide (KFF)3K. Cell-penetrating peptide 547
Fmoc monomers were obtained from AAPPTec, LLC, and lysine monomers were protected with 548
Boc groups. PNA products were precipitated in diethyl ether and purified as trifluoroacetic acid 549 salts via reverse-phase HPLC using a C18 column. 550
PNA-antibiotic interaction assays 551
Three colonies were picked from a plate and used to inoculate three separate overnight 552 cultures in 1 mL CAMHB each. After 16 hours, the culture was diluted 1:10,000 in a 384-well 553 microplate using three biological replicates per condition. The total culture volume for each 554 treatment was 50 µL. PNA were stored at -20 ºC dissolved in 5% v/v DMSO in water. Growth in 555 the plate was monitored with a Tecan GENios (Tecan Group Ltd.) running Magellan™ software 556 (v 7.2) at an absorbance of 590 nm every 20 minutes for 24 hours, with shaking between 557
measurements. 558
Interaction effects were evaluated for significance using a two-way ANOVA test, and S-559 values were calculated with respect for the expected growth inhibition as calculated by the Bliss 560
Independence model. 66 The S-value for a given timepoint was calculated as follows: 561
For a given timepoint (24 hours was used in our analyses), the variable ODAB represents 562 optical density with only carbapenem treatment, OD0 represents the optical density without 563 treatment, ODPNA represents optical density with only antisense-PNA treatment, and ODAB, PNA 564 represents the optical density with a combination treatment. Plus/minus for S-values (Table 1 ) 565 was calculated by propagating standard error values for each term in Equation 1. 566
Other software and resources utilized 567
The clustergram function from MATLAB's Bioinformatics toolbox was used for building 568 heatmaps and dendograms. A Euclidean distance metric, optimal leaf ordering, and average 569 linkage function were used for clustering. Ecocyc 97 was used to gain gene names and 570 descriptions and to define functional classes. NCBI's BLAST 98 was used to predict gene function 571 and to determine similarity of sequences in CUS2B to other bacterial strains. PANTHER 50 was 572 used for statistical overrepresentation tests, with a Bonferroni correction applied to all reported P-573 values. 574
Data availability. 575
The whole genome shotgun sequencing data has been deposited at DDBJ/ENA/GenBank 576 under the accession MSDR00000000.1. The version described in this paper is version 577 MSDR01000000. The RNA sequencing data has been deposited in NCBI's Sequence Read 578
Archive under the accession SRP101716. 
